Skip to main content

Advertisement

SpringerLink
Log in

Applying new Magee equations for predicting the Oncotype Dx recurrence score

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

Breast cancer is one of the most prevalent cancers in women. Oncotype Dx is a multi-gene assay frequently used to predict the recurrence risk for estrogen receptor-positive early breast cancer, with values < 18 considered low risk; ≥ 18 and ≤ 30, intermediate risk; and > 30, high risk. Patients at a high risk for recurrence are more likely to benefit from chemotherapy treatment.

Methods

In this study, clinicopathological parameters for 37 cases of early breast cancer with available Oncotype Dx results were used to estimate the recurrence score using the three new Magee equations. Correlation studies with Oncotype Dx results were performed. Applying the same cutoff points as Oncotype Dx, patients were categorized into low-, intermediate- and high-risk groups according to their estimated recurrence scores.

Results

Pearson correlation coefficient (R) values between estimated and actual recurrence score were 0.73, 0.66, and 0.70 for Magee equations 1, 2 and 3, respectively. The concordance values between actual and estimated recurrence scores were 57.6%, 52.9%, and 57.6% for Magee equations 1, 2 and 3, respectively. Using standard pathologic measures and immunohistochemistry scores in these three linear Magee equations, most low and high recurrence risk cases can be predicted with a strong positive correlation coefficient, high concordance and negligible two-step discordance.

Conclusions

Magee equations are user-friendly and can be used to predict the recurrence score in early breast cancer cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. International Agency for Research on Cancer. Latest world cancer statistics Global cancer burden rises to 14.1 million new cases in 2012: Marked increase in breast cancers must be addressed. World Health Organization. 2013 12 Dec.

  2. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol. 2008;26(19):3153–8.

    Article  PubMed  Google Scholar 

  3. Turner BM, Skinner KA, Tang P, Jackson MC, Soukiazian N, Shayne M, et al. Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. Mod Pathol. 2015;28(7):921–31.

    Article  PubMed  Google Scholar 

  4. Klein ME, Dabbs DJ, Shuai Y, Brufsky AM, Jankowitz R, Puhalla SL, et al. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod Pathol. 2013;26(5):658.

    Article  PubMed  PubMed Central  Google Scholar 

  5. McVeigh TP, Hughes LM, Miller N, Sheehan M, Keane M, Sweeney KJ, et al. The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre. Eur J Cancer. 2014;50(16):2763–70.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Melisko M. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2005;5(1):45–7.

    Google Scholar 

  7. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.

    Article  PubMed  CAS  Google Scholar 

  8. Cronin M, Sangli C, Liu ML, Pho M, Dutta D, Nguyen A, et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor–positive breast cancer. Clin Chem. 2007;53(6):1084–91.

    Article  PubMed  CAS  Google Scholar 

  9. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.

    Article  PubMed  Google Scholar 

  10. Divaris K, Vann WF, Baker AD, Lee JY. Examining the accuracy of caregivers’ assessments of young children’s oral health status. J. Am. Dent. Assoc. 2012;143(11):1237–47.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Gwin K, Pinto M, Tavassoli FA. Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score. Int J Surg Pathol. 2009;17(4):303–10.

    Article  PubMed  CAS  Google Scholar 

  12. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29(32):4273–8.

    Article  PubMed  Google Scholar 

  13. Sahebjam S, Aloyz R, Pilavdzic D, Brisson ML, Ferrario C, Bouganim N, et al. Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score. Br J Cancer. 2011;105(9):1342–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM. Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat. 2012;131(2):413–24.

    Article  PubMed  CAS  Google Scholar 

  15. Tang P, Wang J, Hicks DG, Wang X, Schiffhauer L, McMahon L, et al. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Invest. 2010;28(9):978–82.

    Article  PubMed  Google Scholar 

  16. Clark BZ, Dabbs DJ, Cooper KL, Bhargava R. Impact of progesterone receptor semiquantitative immunohistochemical result on Oncotype DX recurrence score: a quality assurance study of 1074 cases. Appl Immunohistochem Mol Morphol. 2013;21(4):287–91.

    Article  PubMed  CAS  Google Scholar 

  17. Tang G, Cuzick J, Costantino JP, Dowsett M, Forbes JF, Crager M, et al. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor–positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol. 2011;29(33):4365–72.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Biroschak JR, Schwartz GF, Palazzo JP, Toll AD, Brill KL, Jaslow RJ, et al. Impact of oncotype DX on treatment decisions in er-positive, node-negative breast cancer with histologic correlation. Breast J. 2013;19(3):269–75.

    Article  PubMed  Google Scholar 

  19. Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R. Histopathologic variables predict Oncotype DX™ recurrence score. Mod Pathol. 2008;21(10):1255–61.

    Article  PubMed  CAS  Google Scholar 

  20. Van’t Veer LJ, Paik S, Hayes DF. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol. 2005;23(8):1631–5.

    Article  CAS  Google Scholar 

  21. Edén P, Ritz C, Rose C, Fernö M, Peterson C. “Good Old” clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer. 2004;40(12):1837–41.

    Article  PubMed  CAS  Google Scholar 

  22. Orucevic A, Bell JL, McNabb AP, Heidel RE. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data. Breast Cancer Res Treat. 2017;163(1):51–61.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Cancer Registry, Ministry of Health, Jordan. Al-Sayaideh A, Nimri O, Arqoub K, Al-Zaghal M, Halasa W. Cancer incidence in Jordan-2012. https://www.moh.gov.jo/Echobusv3.0/SystemAssets/c602eda7-0c36-49cd-bea1-3484e46c0b97.pdf. Accessed 2 Dec 2017

Download references

Acknowledgements

This research was supported by King Hussein Cancer Center. We would like to thank our colleague from the statistics section Ms. Dalia Al-Rimawi who provided her expertise that greatly assisted the research. We would like to thank Springer Nature Author Services for professional English editing of this manuscript.

Author information

Author notes

  1. Maher Sughayer and Rolla Alaaraj have contributed equally to this work.

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, King Hussein Cancer Center, 202 Queen Rania Street, Al-Jubeiha, P.O. Box 1269, Amman, 11941, Jordan

    Maher Sughayer & Rolla Alaaraj

  2. Department of Surgery, King Hussein Cancer Center, Amman, Jordan

    Ahmad Alsughayer

Authors
  1. Maher Sughayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rolla Alaaraj
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmad Alsughayer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maher Sughayer.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sughayer, M., Alaaraj, R. & Alsughayer, A. Applying new Magee equations for predicting the Oncotype Dx recurrence score. Breast Cancer 25, 597–604 (2018). https://doi.org/10.1007/s12282-018-0860-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-018-0860-x

Keywords

Search

Navigation